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OBJECTIVES: To analyze the cost effectiveness of patelet rich plasma versus corti-
costeroids in the treatment of lateral epicondylitis in a Norwegian setting.
METHODS: A probabilistic Markov model was developed in Microsoft Excel, based
on clinical data from two papers reporting results from a randomized double blind
clinical trial comparing the effect of platelet rich plasma (L-PRP,n49) to cortico-
steroids (CCS, n51) as treatment of lateral epicondylitis (Peerbooms et al 2010,
Gosens et al 2011). The primary outcome of these papers, were Disability of Arm,
Shoulder and Hand (DASH) and the Numerical Pain Visual Analogue Scale (NPRS-
VAS). The study which was conducted in The Netherlands, showed statistically
significant differences on the visual analogue scale and the DASH in favor of L-PRP
after 6, 12 and 24 months. In order to make a cost utility analysis, the VAS-scores
were mapped to EQ-5D, using the method suggested in Dixon et al 2011. In this
study the derived utility values for a series of EQ-5D health states replaced the pain
value with the NPRSVAS, thereby allowing a greater range of pain intensities to be
captured and included in economic analyses. This raises an issue regarding trans-
ferability of QALY-values. Nord E. 1991 concludes that QALY-values elicited in
Norway, The Netherlands, England or Sweden can be used for medical decision
making purposes in any of the other three countries.RESULTS:The results show an
incremental cost effectiveness ratio of € 5 000 per QALY. This is well within what is
considered cost effective in Norway. The probabilistic analysis demonstrates that
the probability of L-PRP being the cost effective alternative is as high as 99% even
when the willingness to pay for additional QALY is as low as € 13 000.
CONCLUSIONS: Compared to corticosteroids, treating lateral epicondylitis with
L-PRP represents the cost effective treatment strategy in Norway.
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OBJECTIVES: The purpose of this study was to estimate the cost-effectiveness of
two therapeutic strategies starting either with Sacral Neuromodulation (SNM) or
Botulinum Neurotoxin A (BTX-A) in the treatment of overactive bladder (OAB) wet
in Italy. METHODS: A 10-year decisional model was developed to assess costs and
outcomes (Quality-Adjusted Life Years – QALYs – gained) associated with the two
pathways from the perspective of the Italian National Healthcare System (INHS).
Clinical inputs were derived from the literature review and validated by key clini-
cians in Italy. Unit costs were derived from public sources. Costs for hospital pro-
cedures and inpatient stay were derived from one of the centres involved in the
study to reflect real costs incurred for SNM implant. Univariate sensitivity analyses
(DSA) were conducted to determine whether results were insensitive to variations
in uncertain parameters. Probabilistic sensitivity analyses (PSA) were performed to
derive cost-effectiveness acceptability curves. RESULTS: Preliminary results
showed that at 10 years SNM is a cost-effective strategy. Cumulative costs were
€33,897 and €33,572 while cumulative QALYs were 7.55 and 6.80 for SNM and BTX-A
respectively. A 4% decrease of incontinence episodes was also observed for SNM
compared with BTX-A. DSA demonstrated the robustness of the results. PSA re-
sults suggested that 99.9% of the 1000 Monte Carlo iterations fell within a €30,000
cost-effectiveness threshold considered acceptable for a marginal unit of
effectiveness. CONCLUSIONS: A therapeutic strategy starting with SNM compared
to one starting with BTX for patients with idiopathic OAB-wet is cost-effective for
the Italian INHS.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat. Its
prevalence has been increasing worldwide. Antiarrhythmic drug therapy is a com-
monly-used treatment for paroxysmal AF , and catheter ablation has become an
important treatment alternative. The purpose of this study was to assess the cost-
effectiveness of catheter ablation compared to antiarrhythmic drug (AAD) therapy
for the treatment of paroxysmal AF in the UK. METHODS: A Markov simulation
model was developed for a hypothetical cohort of 55-year-old patients with drug-
refractory paroxysmal AF and a low stroke risk. The model treatment arms were
catheter ablation and AAD mono-therapy. The model was created to assess the
costs and quality-adjusted life-years over a lifetime horizon. Clinical efficacy of
catheter ablation and AAD therapy were modeled based on the results of a recently
published randomized controlled trial (Wilber et al., 2010). Utilities and other tran-
sition probabilities were drawn from the published literature. Costs were specific to
the UK. RESULTS: The incremental cost-effectiveness ratio for catheter ablation
versus AAD therapy ranged from £12,500 to £15,300 per quality-adjusted life-year.
Over a lifetime horizon, the quality-adjusted life expectancy ranged from 11.75 to
12.20 years for catheter ablation compared to 11.00 to 11.35 years for AAD therapy.
Model results were most sensitive to ablation costs, probability of successful abla-
tion treatment, probability of revision to AF, and probability of successful AAD
therapy. CONCLUSIONS: Catheter ablation appears to be cost-effective compared
to AAD therapy among patients who had drug refractory paroxysmal AF in the UK
population when using a cost-effectiveness threshold of £20,000.
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A FIVE-YEAR MARKOV MODEL EVALUATING THE COST-UTILITY OF NASHA/DX
FOR THE TREATMENT OF FECAL INCONTINENCE: A UNITED STATES
PERSPECTIVE
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OBJECTIVES: To estimate the costs and outcomes associated with the treatment of
NASHA/Dx (Solesta®) for fecal incontinence (FI) compared with sacral nerve stim-
ulation (InterStim®) and anal sphincteroplasty. METHODS: A five-year Markov
model was developed to analyze the cost-utility associated with: 1) NASHA/Dx; 2)
sacral nerve stimulation (SNS); and 3) anal sphincteroplasty (AS) after failure of
conservative therapy. Costs and outcomes were based on the published literature
and other public sources. Costs and QALYs were discounted at a rate of 3% annu-
ally. Probability sensitivity analyses were used to estimate the robustness of the
base case and scenarios. The probability and utility variables were modeled as
beta-distributions; costs were modeled as lognormal distributions. One-way sen-
sitivity analyses were used to evaluate the impact of variations related to key cost
variables. A willingness-to-pay (WTP) analysis was conducted for a threshold of
twice the US GDP per capita; cost-effectiveness acceptability curves were con-
structed. ICERs less than the specified threshold are considered cost-effective.
RESULTS: The base case Markov model yielded an incremental cost-effectiveness
ratio (ICER) for NASHA/Dx vs. conservative therapy (CT) of $30,123 / QALY (Quality
Adjusted Life Year). The ICER for SNS vs. CT was $51,187 / QALY; the ICER for AS vs.
CT was $56,564 / QALY. A sensitivity analysis for the long-term effectiveness of
NASHA/Dx resulted in an ICER of $40,327 for NASHA/Dx vs. CT. Probabilistic sen-
sitivity analysis demonstrated that NASHA/Dx was cost-effective for 78% of the
simulations at a threshold of $70,654 / QALY gained. CONCLUSIONS: For FI pa-
tients, NASHA/Dx has demonstrated cost-effectiveness. Due to higher acquisition
costs, SNS and anal sphincteroplasty were associated with larger ICERs. Sensitivity
analyses indicated NASHA/Dx was cost-effective under all scenarios modeled.
WTP analyses demonstrated that NASHA/Dx was highly probable to be cost-effec-
tive in the US context.
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OBJECTIVES: To evaluate the metabolic effect of adding continuous glucose mon-
itoring (CGM) to insulin pump therapy and the impact of CGM on medical resource
utilization METHODS: Eighty-one adults & seventy-two children with Type 1 dia-
betes participated in a multicenter, randomized, controlled, cross-over study. Fol-
lowing a one month run-in period, subjects were randomized to CGM Sensor-ON or
Sensor-OFF arms for six months, following a four month wash-out period subjects
crossed over to the other treatment arm for six additional months. Health care
resources utilization data was collected for both arms at baseline and at each study
visit. RESULTS: Sensor use significantly improved glycemic control resulting in an
HbA1c reduction of -0.43% in the intention to treat population. There was no sta-
tistically significant difference in the average total daily amount of insulin used
between Sensor-ON and Sensor-OFF groups both in children or adults. There were
statistically significant reductions in the average weekly number of finger-prick
tests observed in Sensor-ON vs. Sensor-OFF period (-3 tests/week in adults and -5
tests/week in children,) resulting in 140€ (adults) and 234€ (children) yearly cost
reduction. There was no significant difference in the number of diabetes related
hospitalizations but the duration of the stay tended to be less with Sensor-ON vs
Sensor-OFF (Adults; 2.2 vs 2.5 days and Children; 1.5 vs 2.0 days). In the per-protocol
population children missed significantly less days of school during the Sensor–ON
vs. Sensor-OFF periods (13 vs 42 days, p0.0046). CONCLUSIONS: Adding CGM to
pump therapy significantly improved metabolic control in adults and children,
without increasing insulin dosage and concomitantly reducing the number of fin-
ger-prick tests. Using the sensor five or more days per week significantly reduced
absence from school in children with type 1 diabetes.
MEDICAL DEVICE/DIAGNOSTICS - Patient-Reported Outcomes & Patient
Preference Studies
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THE USE OF MULTI-CRITERIA DECISION ANALYSIS TO ELICIT COLORECTAL
CANCER SCREENING PREFERENCES
Hummel JM, Steuten L, Groothuis-Oudshoorn KGM, Mulder N, IJzerman MJ
University of Twente, Enschede, The Netherlands
OBJECTIVES: Despite the expected health benefits of colorectal cancer screening
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